乳腺癌数字乳腺断层合成筛查中肿瘤特征与分子亚型:马尔默乳腺断层合成筛查试验
马尔默乳腺断层合成筛查试验为前瞻性人群筛查试验,比较单视图数字乳腺断层合成(DBT)与双视图数字乳腺摄影(DM)。DBT单独检出的额外浸润癌在肿瘤大小≤20 mm、淋巴结阴性及Luminal A样亚型分布上与DM检出者无差异,提示DBT筛查不改变筛查检出癌的预测与预后特征。
要点
- DBT单独检出癌与DM检出癌在肿瘤≤20 mm比例上无差异(86% vs 85%,P=.88)。
- 两组淋巴结阴性率无差异(75% vs 74%,P=.89)。
- Luminal A样亚型占比无差异(53% vs 46%,P=.48)。
核心结论
- DBT筛查检出的额外癌生物学特征与DM检出者相似,多数为早期Luminal A样癌,DBT筛查不改变筛查检出癌的预测与预后特征。
研究设计与样本
- 前瞻性人群筛查试验(马尔默乳腺断层合成筛查试验),纳入14848名女性(平均年龄57岁±10,范围40-76岁),比较单视图DBT与双视图DM,浸润癌按St Gallen标准分类。
诊断标准与关键数值
- 共检出139个癌,其中118个浸润癌、21个导管原位癌;DBT单独检出37个额外浸润癌(36个有完整亚型与分期),DM检出81个癌(80个有完整分期);肿瘤≤20 mm比例DBT组86%(31/36) vs DM组85%(68/80),P=.88;淋巴结阴性比例DBT组75%(27/36) vs DM组74%(59/80),P=.89;Luminal A样亚型比例DBT组53%(19/36) vs DM组46%(37/81),P=.48。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Screening accuracy can be improved with digital breast tomosynthesis (DBT). To further evaluate DBT in screening, it is important to assess the molecular subtypes of the detected cancers. Purpose To describe tumor characteristics, including molecular subtypes, of cancers detected at DBT compared with those detected at digital mammography (DM) in breast cancer screening. Materials and Methods The Malmö Breast Tomosynthesis Screening Trial is a prospective, population-based screening trial comparing one-view DBT with two-view DM. Tumor characteristics were obtained, and invasive cancers were classified according to St Gallen as follows: luminal A-like, luminal B-like human epidermal growth factor receptor (HER)2-negative/HER2-positive, HER2-positive, and triple-negative cancers. Tumor characteristics were compared by mode of detection: DBT alone or DM (ie, DBT and DM or DM alone). χ2 test was used for data analysis. Results Between January 2010 and February 2015, 14 848 women were enrolled (mean age, 57 years ± 10; age range, 40-76 years). In total, 139 cancers were detected; 118 cancers were invasive and 21 were ductal carcinomas in situ. Thirty-seven additional invasive cancers (36 cancers with complete subtypes and stage) were detected at DBT alone, and 81 cancers (80 cancers with complete stage) were detected at DM. No differences were seen between DBT and DM in the distribution of tumor size 20 mm or smaller (86% [31 of 36] vs 85% [68 of 80], respectively; P = .88), node-negative status (75% [27 of 36] vs 74% [59 of 80], respectively; P = .89), or luminal A-like subtype (53% [19 of 36] vs 46% [37 of 81], respectively; P = .48). Conclusion The biologic profile of the additional cancers detected at digital breast tomosynthesis in a large prospective population-based screening trial was similar to those detected at digital mammography, and the majority were early-stage luminal A-like cancers. This indicates that digital breast tomosynthesis screening does not alter the predictive and prognostic profile of screening-detected cancers. © RSNA, 2019.
引用
- Johnson K, Zackrisson S, Rosso A, et al. Tumor Characteristics and Molecular Subtypes in Breast Cancer Screening with Digital Breast Tomosynthesis: The Malmö Breast Tomosynthesis Screening Trial. Radiology. 2019. PMID: 31478799. doi:10.1148/radiol.2019190132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。